Core Insights - The article discusses the author's background in economics and politics, emphasizing expertise in economic development and extensive experience in executive management within the insurance and reinsurance sectors [1]. Group 1 - The author has 36 years of experience in executive management, with a focus on insurance/reinsurance and the Global and Asia Pacific markets [1]. - The author possesses extensive knowledge of climate change and ESG (Environmental, Social, and Governance) factors [1]. - The author invests in a personal capacity, indicating a hands-on approach to investment [1].

Core Viewpoint - Concentrix Corporation's stock dropped over 16% in pre-market trading following third-quarter earnings that fell short of expectations, despite revenue exceeding guidance and an upward revision of the full-year outlook [1]. Financial Performance - The company reported adjusted earnings per share of $2.78 for the quarter ending August 31, which was below analyst expectations of $2.86 [2]. - Revenue for the quarter was $2.48 billion, surpassing expectations of $2.46 billion and reflecting a 4% year-on-year increase. On a constant currency basis, revenue grew by 2.6%, exceeding guidance [2]. - Profitability metrics showed a decline, with the adjusted operating margin falling to 12.3% from 13.9% a year ago, and the adjusted EBITDA margin decreasing to 14.5% from 16.3% [2]. Future Outlook - For the fourth quarter, Concentrix projected revenue between $2.525 billion and $2.550 billion, indicating a constant currency growth of 1.5% to 2.5% [3]. - The full-year revenue guidance was raised to a range of $9.798 billion to $9.823 billion, which corresponds to a constant currency growth of 1.75% to 2.0% [3].

Core Viewpoint - Concentrix's shares are experiencing a significant decline following the release of its Q3 2025 financial results, which disappointed investors despite a revenue beat [1][3]. Financial Performance - Concentrix reported Q3 2025 earnings per share (EPS) of $2.78, falling short of analysts' expectations of $2.87 [3]. - The company achieved revenue of $2.48 billion for Q3 2025, exceeding the anticipated $2.46 billion, marking a year-over-year revenue increase of 4% [4][5]. Future Guidance - Management has revised its fiscal 2025 adjusted EPS guidance down to a range of $11.11 to $11.23, compared to the previous expectation of $11.18 to $11.77 [3][5]. Investment Considerations - Despite the disappointing earnings and guidance, Concentrix offers a forward yield of 2.6% and has maintained a conservative payout ratio averaging 15% over the past five years, which may appeal to income-focused investors [5][6].

Core Viewpoint - Concentrix Corporation reported an earnings per share (EPS) of $2.78, which was below the expected $2.88, indicating a negative surprise of 3.47% [1]. Financial Performance - The actual revenue for the quarter ending August 2025 was approximately $2.48 billion, slightly below the forecasted $2.53 billion, but it exceeded the Zacks Consensus Estimate by 1.02% [2]. - Revenue grew by 4% compared to $2.39 billion in the same quarter of the previous year, and on a constant currency basis, it increased by 2.6% [2]. - Operating income for the quarter was $147 million, representing 5.9% of the revenue, highlighting operational efficiency [5]. Stock Market Reaction - Following the earnings report, Concentrix's stock price experienced a decline, and the company adjusted its fiscal 2025 earnings guidance downwards [3]. Shareholder Returns - Concentrix plans to return over $240 million to shareholders in fiscal 2025 and has announced an increase in its quarterly dividend [3]. Valuation Metrics - The company has a price-to-earnings (P/E) ratio of approximately 14.24, a price-to-sales ratio of about 0.36, and an enterprise value to sales ratio of around 0.83 [4]. - The enterprise value to operating cash flow ratio is approximately 11.22, indicating the company's effectiveness in generating cash from operations [4]. - Concentrix's debt-to-equity ratio is approximately 1.14, and its current ratio is about 1.61, reflecting its ability to meet short-term liabilities [5]. - The earnings yield stands at about 7.02%, representing the return on investment [5].

Core Insights - The customer-experience company has reduced its fiscal-year outlook, indicating potential challenges in meeting previous financial expectations [1] Summary by Categories Financial Performance - The company has adjusted its revenue projections downward, reflecting a more cautious approach to its financial outlook for the fiscal year [1] Market Impact - This revision in outlook may signal broader market challenges within the customer-experience sector, potentially affecting investor confidence and market positioning [1] Strategic Considerations - The company’s decision to lower its fiscal-year guidance suggests a need for reassessment of its strategic initiatives and operational efficiencies to navigate current market conditions [1]

Core Viewpoint - Poste Italiane is contemplating the introduction of an annual management fee for users of its digital identity service, as indicated by analysts following a company briefing [1] Group 1 - The potential annual management fee is part of Poste Italiane's strategy to enhance its digital services [1] - Analysts have highlighted this consideration in their daily reports, suggesting it may impact user engagement and revenue [1]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Top KingWin Ltd (WAI) has increased by 79% to $5.68 - Robo.ai Inc. (AIIO) is up 16% at $2.84 - Amplify Energy Corp. (AMPY) has risen by 12% to $6.53 - Diginex Limited (DGNX) is up 9% at $14.50 - MasterBrand, Inc. (MBC) has increased by 9% to $14.15 - GLOBALFOUNDRIES Inc. (GFS) is up 8% at $35.69 - Crinetics Pharmaceuticals, Inc. (CRNX) has risen by 7% to $38.50 - Aquestive Therapeutics, Inc. (AQST) is up 7% at $5.68 - American Woodmark Corporation (AMWD) has increased by 6% to $69.40 - NLS Pharmaceutics AG (NLSP) is up 5% at $2.17 [3] Premarket Losers - Concentrix Corporation (CNXC) has decreased by 21% to $43.05 - N2OFF, Inc. (NITO) is down 20% at $4.40 - SciSparc Ltd. (SPRC) has fallen by 16% to $5.11 - Legacy Education Inc. (LGCY) is down 13% at $10.68 - DarioHealth Corp. (DRIO) has decreased by 12% to $11.99 - AlphaTON Capital Corp. (ATON) is down 12% at $5.50 - SHF Holdings, Inc. (SHFS) has fallen by 10% to $6.20 - Fusion Fuel Green PLC (HTOO) is down 8% at $4.55 - Linkage Global Inc (LGCB) has decreased by 8% to $2.19 - PepGen Inc. (PEPG) is down 7% at $5.42 [4]

Core Insights - U.S. stock futures showed mixed results, with Dow futures up approximately 0.1% on Friday [1] - Concentrix Corporation reported disappointing third-quarter adjusted EPS results and lowered its FY25 adjusted EPS guidance, leading to a significant drop in its share price [1][2] Concentrix Corporation - Concentrix reported quarterly earnings of $2.78 per share, missing the Street estimate of $2.86 [2] - Quarterly revenue was $2.48 billion, surpassing the analyst consensus estimate of $2.45 billion [2] - The company reduced its fiscal 2025 adjusted EPS guidance to a range of $11.11 to $11.23, below the previous estimate of $11.69 [2] - Concentrix raised its revenue outlook for FY25 to between $9.79 billion and $9.82 billion, compared to the prior estimate of $9.77 billion [2] - Shares of Concentrix fell 20.5% to $43.73 in pre-market trading following the earnings report [2] Other Stocks - DarioHealth Corp. saw a decline of 18.9% to $11.10 in pre-market trading after a significant increase the previous day [5] - Legacy Education Inc. dropped 13.3% to $10.68 after reporting worse-than-expected fourth-quarter EPS results [5] - Apellis Pharmaceuticals, Inc. decreased by 9.5% to $20.12 in pre-market trading [5] - Pharming Group N.V. fell 9.1% to $13.45, while Kingsoft Cloud Holdings Limited declined 7.5% to $16.15 after announcing a new share offering [5] - Other notable declines included IREN Limited down 7.4% to $42.85 and LuxExperience B.V. down 6.3% to $7.89 [5]

Core Insights - U.S. stock futures showed mixed results, with Dow futures up approximately 0.1% on Friday [1] - Concentrix Corporation reported disappointing third-quarter adjusted EPS results and lowered its FY25 adjusted EPS guidance, leading to a significant drop in its share price [1][2] Concentrix Corporation - Concentrix reported quarterly earnings of $2.78 per share, missing the Street estimate of $2.86 [2] - Quarterly revenue was $2.48 billion, exceeding the analyst consensus estimate of $2.45 billion [2] - The company reduced its fiscal 2025 adjusted EPS guidance to a range of $11.11 to $11.23, below the previous estimate of $11.69 [2] - Concentrix raised its revenue outlook for FY25 to between $9.79 billion and $9.82 billion, compared to the prior estimate of $9.77 billion [2] - Shares of Concentrix fell 20.5% to $43.73 in pre-market trading following the earnings report [2] Other Stocks in Pre-Market Trading - DarioHealth Corp. saw a decline of 18.9% to $11.10 after a previous surge of 44% due to a strategic review announcement [5] - Legacy Education Inc. dropped 13.3% to $10.68 after reporting worse-than-expected fourth-quarter EPS results [5] - Apellis Pharmaceuticals, Inc. fell 9.5% to $20.12 in pre-market trading [5] - Pharming Group N.V. decreased by 9.1% to $13.45 [5] - Kingsoft Cloud Holdings Limited declined 7.5% to $16.15 after announcing a new share offering [5] - IREN Limited dipped 7.4% to $42.85 [5] - LuxExperience B.V. fell 6.3% to $7.89 after a previous gain of 3% following its fourth-quarter financial results [5] - YD Bio Ltd dropped 6% to $13.40 [5] - VNET Group, Inc. declined 5.3% to $10.54 [5]

Company News - Heritage Financial Corp announced plans to acquire Olympic Bancorp in an all-stock deal valued at $176.6 million, with Heritage Financial shares falling 0.2% to close at $24.60 [2] - Inventiva S.A. is expected to report a loss of 41 cents per share on revenue of $5.31 million for the first half, with shares gaining 8.3% to close at $6.01 [2] - Concentrix Corp reported worse-than-expected earnings for Q3 and issued weak guidance for Q4, leading to a 22.5% drop in shares to $42.62 in after-hours trading [2] - Costco Wholesale Corp reported Q4 revenue of $86.16 billion, exceeding analyst estimates of $86.12 billion, and adjusted earnings of $5.87 per share, beating estimates of $5.80, with shares slipping 0.9% to $935.04 in after-hours trading [2] - LightPath Technologies Inc posted a wider-than-expected loss of 16 cents per share for Q4, missing the analyst estimate of a 4-cent loss, while quarterly revenue of $12.21 million beat estimates and increased from $8.63 million year-over-year, with shares falling 2.5% to $6.34 in after-hours trading [2]